Aldevron, Ginkgo Bioworks achieve mRNA manufacturing breakthrough

By The Science Advisory Board staff writers

August 10, 2021 --

Aldevron and partner Ginkgo Bioworks said that their strategic partnership has led to a manufacturing breakthrough for an enzyme often used in manufacturing mRNA therapies and vaccines.

The two companies, which have been working together since early 2021 to optimize the production of mRNA vaccine components, said they have achieved an over 10 times more efficient manufacturing process for the vaccinia capping enzyme. Aldevron holds the exclusive rights to the protocol conditions of the newly developed manufacturing process.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.